NIGHTSTARX LIMITED Revenue and Competitors

London, UK

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • NIGHTSTARX LIMITED's estimated annual revenue is currently $16.1M per year.(i)

Employee Data

    NIGHTSTARX LIMITED's People

    NameTitleEmail/Phone
    Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
    #1
    $64.5M32110%N/AN/A
    #2
    $25.5M1275%N/AN/A
    #3
    $115.6M5752%N/AN/A
    #4
    $21.7M1084%N/AN/A
    #5
    $44.8M2239%N/AN/A
    #6
    $15.1M75-67%N/AN/A
    #7
    $16.1MN/AN/AN/A
    #8
    $84.4M4200%N/AN/A
    #9
    $8.8M4410%N/AN/A
    #10
    $31M15428%N/AN/A
    Add Company

    What Is NIGHTSTARX LIMITED?

    Nightstar Therapeutics plc (NASDAQ: NITE) is a leading clinical-stage gene therapy company focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases including choroideremia, X-linked retinitis pigmentosa and Best vitelliform macular dystrophy.

    keywords:N/A

    N/A

    Total Funding

    N/A

    Number of Employees

    $16.1M

    Revenue (est)

    N/A

    Employee Growth %

    N/A

    Valuation

    N/A

    Accelerator

    NIGHTSTARX LIMITED News

    2022-03-22 - Disease-specific assessment of Vision Impairment in Low ...

    Besides the VILL, only a limited number of PRO instruments were designed to ... LinBioscience, NightStarX, Novartis, Optos, Pixium Vision,...

    2022-03-22 - Purespring Positive About Prospects Despite Burst Biotech ...

    ... Therapeutics Limited and its AAV2-based one-time investigational ... manufacturing and controls (CMC) for its NightstaRx Therapeutics...

    2019-03-20 - Nightstar Therapeutics plc files 10-K

    Under the SME Scheme, our principal research subsidiary company, NightstaRx Limited, may be eligible to surrender the trading losses that